Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SCYNEXIS INC (SCYX)

SCYNEXIS wins BARDA contract worth up to $214 million for SCY-247 antifungal

Positive Impact 4 of 5 product/contract Written later

SCYNEXIS entered a contract with the U.S. Biomedical Advanced Research and Development Authority to develop its SCY-247 antifungal candidate, with potential non-dilutive funding of up to $214 million if all options are exercised. The initial base period provides approximately $18.5 million to advance SCY-247 into a Phase 2 study in patients with invasive candidiasis. The company says its SCY-770 development plans and cash runway into 2029 are unchanged.

Key points

  • Contract signed September 25, 2026; base period starts September 2026 with approximately $18.5 million
  • Potential total funding up to $214 million; BARDA may exercise up to six options extending the term up to ten years
  • Cost-share arrangement; company expects to fund its share of near-term SCY-247 costs within its existing operating plan
  • Full contract to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026, with confidential terms redacted

The filing

CompanySCYNEXIS INC (SCYX)
Form8-K, current report
Filed with the SECSep 28, 2026, 4:01 PM ET
Accession number0001178253-26-000037

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.